BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31489635)

  • 1. Residual risk of infection with blood-borne viruses in potential organ donors at increased risk of infection: systematic review and meta-analysis.
    Waller KM; De La Mata NL; Kelly PJ; Ramachandran V; Rawlinson WD; Wyburn KR; Webster AC
    Med J Aust; 2019 Nov; 211(9):414-420. PubMed ID: 31489635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey.
    Butler T; Boonwaat L; Hailstone S; Falconer T; Lems P; Ginley T; Read V; Smith N; Levy M; Dore G; Kaldor J
    Aust N Z J Public Health; 2007 Feb; 31(1):44-50. PubMed ID: 17333608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.
    Soldan K; Barbara JA; Ramsay ME; Hall AJ
    Vox Sang; 2003 May; 84(4):274-86. PubMed ID: 12757501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV.
    Crofts N; Hopper JL; Milner R; Breschkin AM; Bowden DS; Locarnini SA
    Eur J Epidemiol; 1994 Dec; 10(6):687-94. PubMed ID: 7672048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.
    Chiavetta JA; Escobar M; Newman A; He Y; Driezen P; Deeks S; Hone DE; O'Brien SF; Sher G
    CMAJ; 2003 Oct; 169(8):767-73. PubMed ID: 14557314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
    Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
    Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India.
    Ray Saraswati L; Sarna A; Sebastian MP; Sharma V; Madan I; Thior I; Pulerwitz J; Tun W
    BMC Public Health; 2015 Jul; 15():726. PubMed ID: 26223866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection.
    Bhattacharya P; Chandra PK; Datta S; Banerjee A; Chakraborty S; Rajendran K; Basu SK; Bhattacharya SK; Chakravarty R
    World J Gastroenterol; 2007 Jul; 13(27):3730-3. PubMed ID: 17659734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide nucleic acid amplification testing of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow-up study of nucleic acid amplification positive donors.
    Japanese Red Cross NAT Screening Research Group
    Jpn J Infect Dis; 2000 Jun; 53(3):116-23. PubMed ID: 10957709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
    Seed CR; Kiely P; Keller AJ
    Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS).
    Glynn SA; Kleinman SH; Schreiber GB; Busch MP; Wright DJ; Smith JW; Nass CC; Williams AE
    JAMA; 2000 Jul; 284(2):229-35. PubMed ID: 10889598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C; Araújo F
    Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroepidemiology of viral infections among intravenous drug users in northern California.
    Zeldis JB; Jain S; Kuramoto IK; Richards C; Sazama K; Samuels S; Holland PV; Flynn N
    West J Med; 1992 Jan; 156(1):30-5. PubMed ID: 1310362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England.
    Edeh J; Spalding P
    J Public Health Med; 2000 Dec; 22(4):531-9. PubMed ID: 11192282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran.
    Moradi G; Hajarizadeh B; Rahmani K; Mohamadi-Bolbanabad A; Darvishi S; Zareie B; Zavareh FA; Sharafi H; Alavian SM; Ramazani R; Eftekhar M; Radfar SR; Piroozi B; Gouya MM
    Int J Drug Policy; 2019 Nov; 73():129-134. PubMed ID: 31654935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Hepatitis B Virus, Hepatitis C Virus, and Syphilis Coinfection in People With HIV/AIDS Contracted Through Different Sources: Retrospective Study.
    Yang R; Yuan R; Gui X; Ke H; Zhuang K; Hu H; Li L; Feng L; Yu X; Yan Y; Luo M
    JMIR Public Health Surveill; 2024 Feb; 10():e46750. PubMed ID: 38412004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.